THE TAPE
CGON · Biotechnology · $7.5B

CG Oncology, Inc. Common stock

$84.78▲ +13.95%
Last close
Relative strength
94RS
of 99, against every stock▲ +47 on the month
Powering up
Developing
+9.7%
six months against Biotechnology
52-week range
−9.8%
from the high
$37.01$93.95
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue −4% on a year ago
Why it is on no screen

CGON passes every check below but is not on a screen — the screens also require the base to be the most recent structure, which this one is not.

A base has formed12.4 weeks, from 59.22 to 80.97.
Long enough to count12.4 weeks against 3 needed.
Shallow enough26.9% deep against 35% allowed.
Close to its pivot+4.7% from the pivot; listed down to -20%.
Relative strengthRS 94 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$79.62
-6.1% · tested 7× · last 6 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

CG Oncology, Inc. Common stock is not on any of the screens right now. Its relative strength rating is 94, and it sits in Biotechnology.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+37.7%
Three months against its industry
+18.5%
Six months against its industry
+9.7%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 5.8% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$6.2M
-3.7% year on year
Operating margin
-4293.5%
Net margin
-3851.2%
Free cash flow
$-189.2M
-2.5% of market cap
Price to sales
1218.8×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 6
Key takeaway
Cash flow is the weak point of the quarter.
Revenue
$1.6M
+38.6% QoQ · -3.7% YoY
Gross margin
—
Net income
−$56.9M
Loss
Free cash flow
−$48.8M
Burning · 1q runway

What the numbers say

  • Revenue -3.7% year over year, +38.6% on the quarter
  • Weak: Net loss $57M, narrower than $79M last quarter
  • Weak: Burning cash: operating cash flow -$48M, free cash flow -$49M, worse than -$47M last quarter · 1 quarter of cash at this burn
  • Weak: Growth externally funded: capex $1M against operating cash flow -$48M; share count +15.8% in a year
  • Good: Net cash $25M · cash $28M
Revenue by quarter
Free cash flow
Net income
shares +15.8% in a year · net cash $25.2M

What is not obvious

  • Weak: Stock compensation $8M added back against negative operating cash flow
  • Weak: Capital intensity: $1M of capex on $2M of revenue this quarter, $2M over four quarters (0.3× revenue). Expansion is not self-funded
Final read
Growth: FLAT · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is operating profit: net loss $57M, narrower than $79M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-14
above 20d & 50d on 3.2x volume at 74.40
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-14
+6.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-14
4.0 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Pulled back while its group leadsTape · 2026-11-12
3 lower closes in a leading group, 50d held, at 72.61
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 59 nights). Against their own sector they have lagged by 0.9%.
Reported resultsFiling · 2026-11-07
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-07
above 20d & 50d on 3.7x volume at 75.99
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-07
+17.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-07
8.9 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
CG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research · 11 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
1
$24,814,454 total
Sold on the open market
10
$2,913,747 total

Bought: Liu Brian Guan-Chyun. Sold: POST LEONARD E, Mulay James.

Not counted above: 10 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-15 POST LEONARD E · Directoroption exercise1,000$600
2026-10-15 POST LEONARD E · Directorsell500$31,240
2026-09-15 POST LEONARD E · Directoroption exercise1,000$600
2026-09-15 POST LEONARD E · Directorsell1,000$72,980
2026-08-14 POST LEONARD E · Directoroption exercise1,000$600
2026-08-14 POST LEONARD E · Directorsell1,000$74,540
2026-07-15 POST LEONARD E · Directoroption exercise1,000$600
2026-07-15 POST LEONARD E · Directorsell1,000$71,170

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy4
Buy9
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
CG Oncology, Inc. Common stock (CGON) — The Tape